Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
NSCLC
KRAS G12C
Metastatic Lung Cancer
Advanced Lung Carcinoma

Interventions

DRUG: BBO-8520
DRUG: Pembrolizumab
DRUG: BBO-10203

Sponsor

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)